Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure.

[1]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[2]  H. Kawai,et al.  Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. , 2001, American heart journal.

[3]  A. Ferreira,et al.  Predictors of prognosis in patients with stable mild to moderate heart failure. , 2000, Journal of cardiac failure.

[4]  J. Yoshikawa,et al.  Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left venticular hypertrophy. , 2000, Metabolism: clinical and experimental.

[5]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[6]  S. Nakatani,et al.  Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. , 2000, Journal of cardiac failure.

[7]  M. Kodama,et al.  Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. , 2000, Journal of cardiovascular pharmacology.

[8]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[9]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[10]  F. Follath,et al.  Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. , 1999, American heart journal.

[11]  H. Hense,et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.

[12]  P. Poole‐Wilson,et al.  Successes and failures of current treatment of heart failure , 1998, The Lancet.

[13]  M. Komajda,et al.  Risk stratification in chronic heart failure. , 1998, European heart journal.

[14]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[15]  M. Landsman,et al.  Comparison between New York Heart Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. , 1992, The American journal of cardiology.

[16]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[17]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.